Latest News Archive

Please select Category, Year, and then Month to display items

UFS communication campaigns recognised by IABC and MACE

09 December 2022 | Story Rulanzen Martin | Photo Barend Nagel

Web read more — From the left: Rulanzen Martin, Lacea Loader, Dr Nitha Ramnath, and Martie Nortjé.

Another year, another round of national and international awards for the Department of Communication and Marketing’s (DCM) campaigns and projects. This year saw DCM pick up an International Association of Business Communicators (IABC) Africa Silver Quill Award of Excellence for Communication Research for Narrative Building Storytelling. This project and subsequent award were in partnership with Development Communication Solutions (DevCom), led by Lacea Loader, Director: Communication and Marketing.

During the 2022 annual Marketing, Advancement and Communication in Education (MACE) Excellence Awards, DCM won four excellence awards. Dr Nitha Ramnath, Deputy Director: Corporate Relations, won a Silver Award of Excellence for the 2021 Rector’s Concert, and a Bronze Award of Excellence for the 2022 Rector’s Concert.

Lacea Loader and Martie Nortjé, Manager: Reputation, Brand and Marketing Management, won a Bronze Award of Excellence for the project ‘UFS – Our Story: The building and implementation of a brand narrative.’ Rounding up the UFS’ winning tally was Website Editor, Rulanzen Martin, who won a MACE Bronze Award of Excellence for the 2021 UFS Deaf Awareness Month (DAM) Campaign. The DAM campaign also received recognition during the 2021 IABC Silver Quill awards, where it won a Silver Quill Award of Excellence.

Awards a perfect opportunity to benchmark

“The awards give recognition to the communication efforts and endeavours undertaken by DCM as the strategic communication partner at the UFS; it also serves as a perfect opportunity to benchmark against peers and the industry. I am extremely proud of what the team has achieved,” says Loader. “It is an honour when our projects receive awards, given the calibre of entries submitted for both the IABC and MACE awards programmes. The IABC awards programme is for all industries, while the MACE awards only recognise higher education institutions,” she says.

For the 2022 MACE Excellence Awards, a total of 95 awards were awarded to 12 institutions from a total of 171 entries.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children

2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept